About: Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN(®)) and Follow-Up Considerations/Recommendations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN(®)) and Follow-Up Considerations/Recommendations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN(®)) and Follow-Up Considerations/Recommendations
Creator	Abraldes, Maximino Adán, Alfredo Armadá, Félix Ascaso, Francisco Cabrera, Francisco Cervera, Enrique Figueroa, Marta Pazos, Marta Pessoa, Bernardete Reyes, Miguel Udaondo, Patricia
Source	Medline; PMC
abstract	Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting between 1 and 6 months) require frequent injections to maintain efficacy, meaning a considerable treatment burden for diabetic patients with multiple comorbidities. Continuous injections needed in some cases are an economic burden for patients/healthcare system, so real-life clinical practice tends to adopt a reactive approach, ie, watch and wait for worsening symptoms, which consequently increases the risk of undertreatment and edema recurrence. On March 7th 2019, a group of experts in retinal medicine and surgery held a roundtable meeting in Madrid, Spain to discuss how to (1) optimize clinical outcomes through earlier use of fluocinolone acetonide (FAc) implant (ILUVIEN(®)) in patients with persistent or recurrent DME despite therapy; and, (2) to provide guidance to assist physicians in deciding which patients should be treated with ILUVIEN. In this regard, a 36-month follow-up consensus protocol is presented. In conclusion, patients that achieve a complete or partial anatomical, and preferably functional, response following one or two intravitreal dexamethasone implants, but with recurrence of edema after 3–4 months, are deemed by the authors most likely to benefit from ILUVIEN, and the switch to FAc implant should not be delayed more than 12 months after the initiation of at least the first dexamethasone implant.
has issue date	2020-07-24(xsd:dateTime)
bibo:doi	10.2147/opth.s252359
bibo:pmid	32801618
has license	cc-by-nc
sha1sum (hex)	86ef637963c1e1160b5569ecab87278bfa8d8773
schema:url	https://doi.org/10.2147/opth.s252359
resource representing a document's title	Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN(®)) and Follow-Up Considerations/Recommendations
has PubMed Central identifier	PMC7398681
has PubMed identifier	32801618
schema:publication	Clin Ophthalmol
resource representing a document's body	covid:86ef637963c1e1160b5569ecab87278bfa8d8773#body_text
is schema:about of	named entity 'economic' named entity '2019' named entity 'needed' named entity 'protocol' named entity 'PARTIAL' named entity 'SYMPTOMS' named entity 'NEEDED' named entity 'ILUVIEN' named entity 'FLUOCINOLONE ACETONIDE' named entity '12 MONTHS' named entity 'PERSISTENT' named entity 'INTRAVITREAL INJECTIONS' named entity 'SWITCH' named entity 'IMPLANTS' named entity 'CONTINUOUS' named entity 'INJECTIONS' named entity 'WORSENING' named entity 'edema' named entity 'adopt' named entity 'functional' named entity 'medicine' named entity 'Madrid' named entity 'dexamethasone' named entity 'regard' named entity 'initiation' named entity 'frequent' named entity 'clinical outcomes' named entity 'edema' named entity 'diabetic macular edema' named entity 'dexamethasone' named entity 'anti-vascular endothelial growth factors' named entity 'intravitreal injections' named entity 'dexamethasone' named entity 'contraindication' named entity 'inflammation' named entity 'treatment options' named entity 'current literature' named entity 'pro re nata' named entity 'extracellular fluid' named entity 'cup-to-disc ratio' named entity 'OCT' named entity 'anti-VEGF therapy' named entity 'inflammatory mediators' named entity 'corticosteroid' named entity 'IOP' named entity 'corticosteroid' named entity 'adverse events' named entity 'Spain' named entity 'glaucoma' named entity 'intravitreal' named entity 'DME' named entity 'reactive oxygen species' named entity 'mmHg' named entity 'Evidence of effectiveness' named entity 'prostaglandin analogues' named entity 'visual acuity' named entity 'retinopathy' named entity 'Fluocinolone' named entity 'DME' named entity 'bevacizumab' named entity 'iatrogenic injury' named entity 'DME' named entity 'DME' named entity 'Ocular hypertension' named entity 'corticosteroids' named entity 'RCTs' named entity 'intravitreal' named entity 'DME' named entity 'DME' named entity 'laser photocoagulation' named entity 'IOP'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software